Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A personalized mRNA cancer vaccine just hit a major milestone. The phase 3 INTerpath-001 trial found that intismeran autogene — a tumor-specific neoantigen therapy — combined with pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with completely resected stage IIB-IV melanoma, compared to pembrolizumab alone. This marks the first phase 3 win for a personalized mRNA-based cancer treatment.
A personalized mRNA cancer vaccine just hit a major milestone. The phase 3 INTerpath-001 trial — a randomized, double-blind, placebo-controlled study involving 1,137 adults with completely resected stage IIB-IV cutaneous melanoma — found that intismeran autogene plus pembrolizumab significantly improved both recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared to pembrolizumab alone. This is the first phase 3 study to demonstrate that a personalized mRNA-based neoantigen therapy can reduce the risk of recurrence or death in this setting.
Intismeran works by analyzing a patient's own tumor to identify its unique mutational "fingerprint," then training the immune system to attack those specific cancer cells. The safety profile of the combination was consistent with what's already known for each agent individually, with no new safety signals identified. Overall survival data are still being collected.
Key Takeaways:
Why it matters: If confirmed with full OS data, intismeran + pembrolizumab could establish a new standard of care in adjuvant melanoma treatment — and signal a broader shift toward personalized mRNA-based immunotherapy across multiple cancer types.
